Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1927913 | 0.81 | VSIR (0.61) | VSIRMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1121101 | 0.81 | MEN1 (0.53) | BACE1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL11637839 | 0.78 | MEN1 (0.46) | BACE1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL27705902 | 0.77 | RAB9A (0.46) | MAPTSMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL9762921 | 0.73 | NPC1 (0.55) | MAPTSMN1; SMN2MEN1KMT2ACYP1A2 | |
| SCHEMBL13950792 | 0.73 | MAPT (0.51) | VSIRMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL9795720 | 0.72 | HTT (0.63) | VSIRMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL13950338 | 0.72 | KCNH3 (0.51) | VSIRMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL9795905 | 0.71 | VSIR (0.54) | VSIRMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL13950343 | 0.70 | KCNH2 (0.54) | VSIRMAPTMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9162988-B2 | Therapeutic or prophylactic agent for allergic dermatitis | TORAY INDUSTRIES, INC. (JP) | 2015-10-20 | — | — | US | disclosed |
| US-20130150390-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | TORAY INDUSTRIES, INC. (JP) | 2013-06-13 | — | — | US | disclosed |
| EP-1840121-B1 | GLYCINE DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2039687-B1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS | TORAY INDUSTRIES (JP) | 2012-05-02 | — | — | EP | disclosed |
| EP-2042171-B1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | TORAY INDUSTRIES (JP) | 2011-05-11 | — | — | EP | disclosed |
| US-7893046-B2 | agent comprises as an effective ingredient a glycine derivative or a pharmaceutically acceptable salt thereof, for example [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid] | TORAY INDUSTRIES, INC. (JP) | 2011-02-22 | — | — | US | disclosed |
| EP-2033637-B1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA | TORAY INDUSTRIES (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-7879837-B2 | administering glycine derivatives such as (E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid, used for the treatment of nervous system disorders | TORAY INDUSTRIES, INC. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20090275599-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS | TORAY INDUSTRIES, INC. (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090253724-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA | TORAY INDUSTRIES, INC. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-7566724-B2 | Glycine derivative and use thereof | TORAY INDUSTRIES, INC. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-20090093508-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | TORAY INDUSTRIES, INC. (JP) | 2009-04-09 | — | — | US | disclosed |
| EP-2042171-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | Toray Industries, Inc. (JP) | 2009-04-01 | — | — | EP | disclosed |
| EP-2039687-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS | Toray Industries, Inc. (JP) | 2009-03-25 | — | — | EP | disclosed |
| EP-2033637-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA | Toray Industries, Inc. (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-20080085910-A1 | Glycine Derivative and Use Thereof | TORAY INDUSTRIES, INC. (JP) | 2008-04-10 | — | — | US | disclosed |
| EP-1840121-A1 | GLYCINE DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2007-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093508-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | HRH2, TSLP, ENPEP | VSIR 1953/4885BACE1 1988/4885MAPT 3547/4885 |
| US-20130150390-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | HRH2, TSLP, ENPEP | VSIR 1953/4885BACE1 1988/4885MAPT 3547/4885 |
| US-20080085910-A1 | Glycine Derivative and Use Thereof | GNMT, SI, SLC7A11 | VSIR 1787/4885BACE1 1073/4885MAPT 2868/4885 |
| US-20090275599-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS | PMP22, MGMT, ENPEP | VSIR 2665/4885BACE1 2042/4885MAPT 3044/4885 |
| US-20090253724-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA | MCL1, ENPEP, SLC7A1 | VSIR 3730/4885BACE1 4778/4885MAPT 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.